Bionano Genomics (BNGO) Registration filing summary

Company overview and business model

• Genome analysis portfolio includes optical genome mapping (OGM) systems, diagnostic and laboratory services, VIA software, and Ionic DNA/RNA purification technology.

• Saphyr and Stratys systems combine instruments, consumables, reagents, and software; VIA integrates OGM, sequencing, and microarray data for genomic analysis.

• Strategy emphasizes cost savings and greater utilization of the installed OGM base, with less focus on new system placements.

• Bionano Laboratories offers an OGM-based FSHD1 test and research services; other testing services were phased out during 2024 and 2025.

Financial performance and metrics

• Recurring net losses and negative cash flows, alongside a significant accumulated deficit, raise substantial doubt about the ability to continue as a going concern; additional capital is needed.

• The filing cites the ability to continue as a going concern within 12 months of the Q2 2026 Form 10-Q filing as dependent on cost management and significant additional financing.

• Public float was $25.58M as of Oct. 30, 2026, based on 13,979,584 non-affiliate shares at $1.83; prior 12-month registered sales under the Form S-3 limit totaled ~$5.94M.

Use of proceeds and capital allocation

• Net proceeds are intended for general corporate purposes, including working capital, R&D, and capital expenditures; specific allocations may be set out in offering supplements.

• Proceeds may fund complementary businesses, products, or technologies, with no current acquisition plans, commitments, or agreements; interim investments may include government obligations and money-market instruments.